A clinical trial involving 986 adults assessed once-weekly efsitora versus once-daily degludec for blood sugar control in type 2 diabetes patients already on basal insulin. Over 78 weeks, efsitora demonstrated a comparable mean reduction in HbA1c (0.81%) to degludec (0.72%), achieving noninferiority. Both dosing regimens showed similar improvements in fasting glucose and hypoglycemia rates, while efsitora resulted in enhanced patient satisfaction due to reduced injection frequency. These findings indicate efsitora as a viable alternative treatment.

Source: The Lancet